Activation of the stress proteome as a mechanism for small molecule therapeutics

Rebecca Deering Brose, Gloria Shin, Martina C. Mcguinness, Tonya Schneidereith, Shirley Purvis, Gao X. Dong, Jeffrey Keefer, Forrest Spencer, Kirby D. Smith

Research output: Contribution to journalArticle

Abstract

Various small molecule pharmacologic agents with different known functions produce similar outcomes in diverse Mendelian and complex disorders, suggesting that they may induce common cellular effects. These molecules include histone deacetylase inhibitors, 4-phenylbutyrate (4PBA) and trichostatin A, and two small molecules without direct histone deacetylase inhibitor activity, hydroxyurea (HU) and sulforaphane. In some cases, the therapeutic effects of histone deacetylase inhibitors have been attributed to an increase in expression of genes related to the disease-causing gene. However, here we show that the pharmacological induction of mitochondrial biogenesis was necessary for the potentially therapeutic effects of 4PBA or HU in two distinct disease models, X-linked adrenoleukodystrophy and sickle cell disease. We hypothesized that a common cellular response to these four molecules is induction of mitochondrial biogenesis and peroxisome proliferation and activation of the stress proteome, or adaptive cell survival response. Treatment of human fibroblasts with these four agents induced mitochondrial and peroxisomal biogenesis as monitored by flow cytometry, immunofluorescence and/or western analyses. In treated normal human fibroblasts, all four agents induced the adaptive cell survival response: heat shock, unfolded protein, autophagic and antioxidant responses and the c-jun N-terminal kinase pathway, at the transcriptional and translational levels. Thus, activation of the evolutionarily conserved stress proteome and mitochondrial biogenesis may be a common cellular response to such small molecule therapy and a common basis of therapeutic action in various diseases. Modulation of this novel therapeutic target could broaden the range of treatable diseases without directly targeting the causative genetic abnormalities.

Original languageEnglish (US)
Article numberdds247
Pages (from-to)4237-4252
Number of pages16
JournalHuman Molecular Genetics
Volume21
Issue number19
DOIs
StatePublished - Oct 2012

Fingerprint

Organelle Biogenesis
Proteome
Histone Deacetylase Inhibitors
Hydroxyurea
Therapeutic Uses
Cell Survival
trichostatin A
Fibroblasts
Adrenoleukodystrophy
Peroxisomes
JNK Mitogen-Activated Protein Kinases
Sickle Cell Anemia
Therapeutics
Heat-Shock Proteins
Fluorescent Antibody Technique
Flow Cytometry
Antioxidants
Pharmacology
Gene Expression
Genes

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Brose, R. D., Shin, G., Mcguinness, M. C., Schneidereith, T., Purvis, S., Dong, G. X., ... Smith, K. D. (2012). Activation of the stress proteome as a mechanism for small molecule therapeutics. Human Molecular Genetics, 21(19), 4237-4252. [dds247]. https://doi.org/10.1093/hmg/dds247

Activation of the stress proteome as a mechanism for small molecule therapeutics. / Brose, Rebecca Deering; Shin, Gloria; Mcguinness, Martina C.; Schneidereith, Tonya; Purvis, Shirley; Dong, Gao X.; Keefer, Jeffrey; Spencer, Forrest; Smith, Kirby D.

In: Human Molecular Genetics, Vol. 21, No. 19, dds247, 10.2012, p. 4237-4252.

Research output: Contribution to journalArticle

Brose, RD, Shin, G, Mcguinness, MC, Schneidereith, T, Purvis, S, Dong, GX, Keefer, J, Spencer, F & Smith, KD 2012, 'Activation of the stress proteome as a mechanism for small molecule therapeutics', Human Molecular Genetics, vol. 21, no. 19, dds247, pp. 4237-4252. https://doi.org/10.1093/hmg/dds247
Brose RD, Shin G, Mcguinness MC, Schneidereith T, Purvis S, Dong GX et al. Activation of the stress proteome as a mechanism for small molecule therapeutics. Human Molecular Genetics. 2012 Oct;21(19):4237-4252. dds247. https://doi.org/10.1093/hmg/dds247
Brose, Rebecca Deering ; Shin, Gloria ; Mcguinness, Martina C. ; Schneidereith, Tonya ; Purvis, Shirley ; Dong, Gao X. ; Keefer, Jeffrey ; Spencer, Forrest ; Smith, Kirby D. / Activation of the stress proteome as a mechanism for small molecule therapeutics. In: Human Molecular Genetics. 2012 ; Vol. 21, No. 19. pp. 4237-4252.
@article{49351f122fb64297b662c292a2197655,
title = "Activation of the stress proteome as a mechanism for small molecule therapeutics",
abstract = "Various small molecule pharmacologic agents with different known functions produce similar outcomes in diverse Mendelian and complex disorders, suggesting that they may induce common cellular effects. These molecules include histone deacetylase inhibitors, 4-phenylbutyrate (4PBA) and trichostatin A, and two small molecules without direct histone deacetylase inhibitor activity, hydroxyurea (HU) and sulforaphane. In some cases, the therapeutic effects of histone deacetylase inhibitors have been attributed to an increase in expression of genes related to the disease-causing gene. However, here we show that the pharmacological induction of mitochondrial biogenesis was necessary for the potentially therapeutic effects of 4PBA or HU in two distinct disease models, X-linked adrenoleukodystrophy and sickle cell disease. We hypothesized that a common cellular response to these four molecules is induction of mitochondrial biogenesis and peroxisome proliferation and activation of the stress proteome, or adaptive cell survival response. Treatment of human fibroblasts with these four agents induced mitochondrial and peroxisomal biogenesis as monitored by flow cytometry, immunofluorescence and/or western analyses. In treated normal human fibroblasts, all four agents induced the adaptive cell survival response: heat shock, unfolded protein, autophagic and antioxidant responses and the c-jun N-terminal kinase pathway, at the transcriptional and translational levels. Thus, activation of the evolutionarily conserved stress proteome and mitochondrial biogenesis may be a common cellular response to such small molecule therapy and a common basis of therapeutic action in various diseases. Modulation of this novel therapeutic target could broaden the range of treatable diseases without directly targeting the causative genetic abnormalities.",
author = "Brose, {Rebecca Deering} and Gloria Shin and Mcguinness, {Martina C.} and Tonya Schneidereith and Shirley Purvis and Dong, {Gao X.} and Jeffrey Keefer and Forrest Spencer and Smith, {Kirby D.}",
year = "2012",
month = "10",
doi = "10.1093/hmg/dds247",
language = "English (US)",
volume = "21",
pages = "4237--4252",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "19",

}

TY - JOUR

T1 - Activation of the stress proteome as a mechanism for small molecule therapeutics

AU - Brose, Rebecca Deering

AU - Shin, Gloria

AU - Mcguinness, Martina C.

AU - Schneidereith, Tonya

AU - Purvis, Shirley

AU - Dong, Gao X.

AU - Keefer, Jeffrey

AU - Spencer, Forrest

AU - Smith, Kirby D.

PY - 2012/10

Y1 - 2012/10

N2 - Various small molecule pharmacologic agents with different known functions produce similar outcomes in diverse Mendelian and complex disorders, suggesting that they may induce common cellular effects. These molecules include histone deacetylase inhibitors, 4-phenylbutyrate (4PBA) and trichostatin A, and two small molecules without direct histone deacetylase inhibitor activity, hydroxyurea (HU) and sulforaphane. In some cases, the therapeutic effects of histone deacetylase inhibitors have been attributed to an increase in expression of genes related to the disease-causing gene. However, here we show that the pharmacological induction of mitochondrial biogenesis was necessary for the potentially therapeutic effects of 4PBA or HU in two distinct disease models, X-linked adrenoleukodystrophy and sickle cell disease. We hypothesized that a common cellular response to these four molecules is induction of mitochondrial biogenesis and peroxisome proliferation and activation of the stress proteome, or adaptive cell survival response. Treatment of human fibroblasts with these four agents induced mitochondrial and peroxisomal biogenesis as monitored by flow cytometry, immunofluorescence and/or western analyses. In treated normal human fibroblasts, all four agents induced the adaptive cell survival response: heat shock, unfolded protein, autophagic and antioxidant responses and the c-jun N-terminal kinase pathway, at the transcriptional and translational levels. Thus, activation of the evolutionarily conserved stress proteome and mitochondrial biogenesis may be a common cellular response to such small molecule therapy and a common basis of therapeutic action in various diseases. Modulation of this novel therapeutic target could broaden the range of treatable diseases without directly targeting the causative genetic abnormalities.

AB - Various small molecule pharmacologic agents with different known functions produce similar outcomes in diverse Mendelian and complex disorders, suggesting that they may induce common cellular effects. These molecules include histone deacetylase inhibitors, 4-phenylbutyrate (4PBA) and trichostatin A, and two small molecules without direct histone deacetylase inhibitor activity, hydroxyurea (HU) and sulforaphane. In some cases, the therapeutic effects of histone deacetylase inhibitors have been attributed to an increase in expression of genes related to the disease-causing gene. However, here we show that the pharmacological induction of mitochondrial biogenesis was necessary for the potentially therapeutic effects of 4PBA or HU in two distinct disease models, X-linked adrenoleukodystrophy and sickle cell disease. We hypothesized that a common cellular response to these four molecules is induction of mitochondrial biogenesis and peroxisome proliferation and activation of the stress proteome, or adaptive cell survival response. Treatment of human fibroblasts with these four agents induced mitochondrial and peroxisomal biogenesis as monitored by flow cytometry, immunofluorescence and/or western analyses. In treated normal human fibroblasts, all four agents induced the adaptive cell survival response: heat shock, unfolded protein, autophagic and antioxidant responses and the c-jun N-terminal kinase pathway, at the transcriptional and translational levels. Thus, activation of the evolutionarily conserved stress proteome and mitochondrial biogenesis may be a common cellular response to such small molecule therapy and a common basis of therapeutic action in various diseases. Modulation of this novel therapeutic target could broaden the range of treatable diseases without directly targeting the causative genetic abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=84866374070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866374070&partnerID=8YFLogxK

U2 - 10.1093/hmg/dds247

DO - 10.1093/hmg/dds247

M3 - Article

C2 - 22752410

AN - SCOPUS:84866374070

VL - 21

SP - 4237

EP - 4252

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 19

M1 - dds247

ER -